First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S127-S130. doi: 10.21037/tlcr.2018.03.06.

Authors

Biagio Ricciuti¹, Rita Chiari¹

Affiliation

¹ Department of Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.

No abstract available

Publication types

Editorial
Comment